Kaitlyn D’Onofrio

DocwireNews

A recent study found a correlation between rheumatoid arthritis (RA) patients&rsquo;&nbsp;multibiomarker&nbsp;disease activity (MBDA) and the use of&nbsp;biologics&nbsp;and&nbsp;Janus kinase (JAK)&nbsp;inhibitors.&nbsp;Researchers evaluated Medicare data from 2011&ndash;2015 and connected RA patients to their MBDA scores, and determined which patients began treatment with a biologic or JAK inhibitor within six months after their MBDA test.&nbsp;&nbsp;<figure class="wp-block-embed-twitter wp-block-embed is-type-rich is-provider-twitter">
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Download the <a href="https://twitter.com/hashtag/RheumatoidArthritis?src=hash&amp;ref_src=twsrc%5Etfw">#RheumatoidArthritis</a> Practice Aids from our recently released activity titled "Improving Outcomes for Patients With Refractory Rheumatoid Arthritis: The Role of JAK Inhibitors". <a href="https://t.co/gceEHg2JiG">https://t.co/gceEHg2JiG</a>
&mdash; PeerView (@PeerView) <a href="https://twitter.com/PeerView/status/1072216940297494528?ref_src=twsrc%5Etfw">December 10, 2018</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
</div>
</figure>A total of 60,596 RA patients were included in the study. Of the patients who had not previously been using biologics&nbsp;or&nbsp;a&nbsp;JAK inhibitor, 9.0% who had a low MBDA&nbsp;score&nbsp;initiated&nbsp;one of these treatments, compared to 11.8% with a moderate MBDA&nbsp;score,&nbsp;and 19.7% with a high MBDA&nbsp;score&nbsp;(p &lt; 0.0001).&nbsp;For patients who were already&nbsp;using&nbsp;biologics&nbsp;or&nbsp;a JAK inhibitor,&nbsp;5.2%, 8.3%, and 13.5% of low, moderate, and high MBDA score patients, respectively,&nbsp;added&nbsp;or switched treatment (p &lt; 0.0001). In multivariable analysis, using low disease MBDA scores as a reference, moderate MBDA score patients&nbsp;had a&nbsp;1.51-fold&nbsp;increased chance of switching&nbsp;(95% CI 1.35&ndash;1.69), and&nbsp;high MBDA patients had a&nbsp;2.62-fold increased chance&nbsp;(2.26&ndash;3.05).&nbsp;<figure class="wp-block-embed-twitter wp-block-embed is-type-rich is-provider-twitter">
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<a href="https://twitter.com/hashtag/ACR18?src=hash&amp;ref_src=twsrc%5Etfw">#ACR18</a> Yoshiya Tanaka presenting phase III <a href="https://twitter.com/hashtag/ClinicalTrial?src=hash&amp;ref_src=twsrc%5Etfw">#ClinicalTrial</a> results demonstrating efficacy of the JAK inhibitor <a href="https://twitter.com/hashtag/peficitinib?src=hash&amp;ref_src=twsrc%5Etfw">#peficitinib</a> in patients with <a href="https://twitter.com/hashtag/RheumatoidArthritis?src=hash&amp;ref_src=twsrc%5Etfw">#RheumatoidArthritis</a>
&mdash; medwireNews (@medwireNews) <a href="https://twitter.com/medwireNews/status/1054096661985853441?ref_src=twsrc%5Etfw">October 21, 2018</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
</div>
</figure>Researchers also observed that high MBDA score patients&nbsp;who&nbsp;added a biologic&nbsp;or JAK inhibitor and underwent another MBDA test but did not have an improved score&nbsp;were more likely to experience RA treatment failure (odds ratio [OR]&nbsp;1.61, 95% CI 1.27&ndash;2.03).&nbsp;<figure class="wp-block-embed-twitter wp-block-embed is-type-rich is-provider-twitter">
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Tracked changes in MBDA scores of patients with <a href="https://twitter.com/hashtag/rheumatoidarthritis?src=hash&amp;ref_src=twsrc%5Etfw">#rheumatoidarthritis</a> reflect changes in the degree of rituximab treatment response. <a href="https://t.co/QqgbBsyoNV">https://t.co/QqgbBsyoNV</a>
&mdash; Rheumatology Advisor (@RheumAdvisor) <a href="https://twitter.com/RheumAdvisor/status/1072196832036642816?ref_src=twsrc%5Etfw">December 10, 2018</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
</div>
</figure>&ldquo;While we cannot provide certainty that the main reason that clinicians switched therapies was the MBDA test result, we note that the median time to add or switch to a new RA treatment was 1-2 months after testing, lending plausibility to the MBDA test being influential in this decision,&rdquo;&nbsp;the study authors wrote.&nbsp;<a href="https://proddocwire.wpengine.com/docwire-pick/study-predictors-tofacitinib-success/" target="_blank" rel="noreferrer noopener">Study: Predictors of Tofacitinib Success in RA Patients</a>&nbsp;<a href="https://cswnews.sharepoint.com/sites/AMCDigitalTeam/Shared%20Documents/DocWire%20News/HOMEPAGE/12.11%20homepage.docx?web=1" target="_blank" rel="noreferrer noopener">Rheumatoid Arthritis Patients with Low Disease Activity Still Have Flareups</a>&nbsp;<a href="https://proddocwire.wpengine.com/docwire-pick/palindromic-rheumatism-rheumatoid-arthritis/" target="_blank" rel="noreferrer noopener">Unique Imaging Sets Palindromic Rheumatism Apart from Rheumatoid Arthritis</a>&nbsp;<a rel="noreferrer noopener" href="https://proddocwire.wpengine.com/abstracts/rheumatoid-arthritis-periodontal-disease/" target="_blank"><g class="gr_ gr_3 gr-alert gr_gramm gr_inline_cards gr_run_anim Grammar only-ins doubleReplace replaceWithoutSep" id="3" data-gr-id="3">Relationship</g> between rheumatoid arthritis and periodontal disease in Korean adults: Data from the Sixth Korea National Health and Nutrition Examination Survey, 2013-2015</a>&nbsp;Sources:&nbsp;<a href="http://www.jrheum.org/content/early/2018/11/12/jrheum.180071">The Journal of Rheumatology</a>, <a href="https://www.mdedge.com/rheumatologynews/article/189743/rheumatoid-arthritis/study-takes-look-real-world-use-mbda-testing">Rheumatology News&nbsp;</a>

Jordana Jampel

Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research

Melanoma

Hatem Soliman, MD

Using Dendritic Cell Vaccines to Boost Neoadjuvant Therapy in HER2+ Breast Cancer

HER2 Breast Cancer

Kathleen Liu, MD

Joel M. Topf, MD, FACP

AKI Approaches and ASN Kidney Health Guidance

NKF Spring Clinical Meetings 2025

Latest News

MBDA Score May Influence RA Patients’ Treatment Choices

Rheumatoid Arthritis

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe